BLOOD STEM CELL
THERAPIES
Our platform technology for generating self-renewing blood stem cells is poised to provide patients with rapid and broad access to consistent, durable, HLA-compatible transgene-free blood stem cell therapies. As the industry’s first off-the-shelf offering, Garuda’s technology has the potential to cure more than 70 diseases and eliminate dependency on donor or patient cells.
LEADERSHIP
Garuda was founded and is supported by experts in blood stem cell and bone marrow transplants as well as leaders with expertise in bringing transformative medicines to patients.
Leadership Team
Dhvanit Shah, Ph.D.
Founder, President, & CEO
James Desiderio, Ph.D.
Chief Regulatory Officer
Giorgia Scapin, Ph.D.
Senior Vice President & Head, Research and Development
Roger Sawhney, M.D.
Chief Financial Officer
The Founders
Dhvanit Shah, Ph.D.
Founder, President, & CEO
Former Principal Faculty,
Harvard Stem Cell Institute
Former Associate Member,
Broad Institute of MIT and Harvard
David Scadden, M.D.
Co-Founder
Co-Director,
Harvard Stem Cell Institute
Gerald and Darlene Jordan
Professor of Medicine, Harvard University
Sean Morrison, Ph.D.
Co-Founder
Investigator,
Howard Hughes Medical Institute
Director, Children’s Research Institute,
UT Southwestern Medical Center
Board of Directors
Dhvanit Shah, Ph.D.
Founder, President, and CEO
Garuda Therapeutics, Inc.
Eric Aguiar, M.D.
Partner
Aisling Capital
Carl Gordon, Ph.D., CFA
Managing Partner
OrbiMed
Shaan C. Gandhi, M.D., D.Phil.
Director
Northpond Ventures
Rahul Singhvi, Sc.D.
Co-Founder and CEO
National Resilience, Inc.
Laurence Reid, Ph.D.
CEO
Decibel Therapeutics
Scientific Advisory Board
David Scadden, M.D.
Co-Director, Harvard Stem Cell Institute
Gerald and Darlene Jordan Professor of Medicine, Harvard University
Sean Morrison, Ph.D.
Investigator, Howard Hughes Medical Institute
Founder & Director, Children’s Research Institute at UT Southwestern Medical Center
Robert Negrin, M.D.
Professor of Medicine, Stanford University
Former Chief of the Division of Blood and Marrow Transplantation, Stanford University
Jerome Ritz, M.D.
Executive Director, Connell and O’Reilly Families Cell Manipulation Core Facility, Dana-Farber Cancer Institute
Professor of Medicine, Harvard Medical School
Marcel van den Brink, M.D., Ph.D.
Head, Division of Hematologic Malignancies &
Alan N. Houghton Chair, Memorial Sloan Kettering Cancer Center
Ivan Maillard, M.D., Ph.D.
Professor of Hematology-Oncology, University of Pennsylvania School of Medicine
Katja G. Weinacht, M.D., Ph.D.
Assistant Professor of Pediatrics, Stanford University School of Medicine
John E. Wagner, M.D.
Distinguished McKnight Professor of Pediatrics, University of Minnesota
Giorgia Scapin, Ph.D.
Harvard Medical School
News
September
7
2022
CAMBRIDGE, Mass. – September 7, 2022 – Garuda Therapeutics (Garuda), a company creating off-the-shelf, durable blood stem cell therapies, today announced the appointment of Roger Sawhney, M.D., as Chief Financial Officer. Dr. Sawhney previously served as Chief Financial Officer and Chief Business Officer at Omega Therapeutics, a pioneer in mRNA-based therapeutics for precision gene modulation. read more →
March
15
2022
CAMBRIDGE, Mass. – March 15, 2022 – Garuda Therapeutics (Garuda), a company creating off-the-shelf, durable blood stem cell therapies, today announced the appointment of James Desiderio, Ph.D. as Chief Regulatory Officer. Dr. Desiderio previously served as Senior Vice President of Regulatory Affairs and Quality at Acceleron Pharma. read more →
January
6
2022
CAMBRIDGE, Mass. – January 6, 2022 – Garuda Therapeutics (Garuda), today announced that Dhvanit Shah, Ph.D., Co-Founder, President and Chief Executive Officer, will present virtually at the 40th Annual J.P. Morgan Healthcare Conference on January 11, 2022 (Tuesday) at 5:30 pm EST. read more →
January
5
2022
CAMBRIDGE, Mass. – January 5, 2022 – Garuda Therapeutics (Garuda), a company creating off-the-shelf, durable blood stem cell therapies, today announced the appointment of Laurence Reid, Ph.D. to its board of directors… read more →
November
8
2021
National Institutes of Health (NIH) features the promise of Garuda Therapeutics technology
“Look at that! Life!” said Deidra Flowers-Williams, a sickle cell disease patient, as she held up a tube with stem cells donated by her sister, Tanisha Flowers. It was just minutes before doctors at the NIH Clinical Center… read more →
September
23
2021
First off-the-shelf, long-term durable blood stem cell platform has potential to cure more than 70 diseases, eliminate dependency on donor or patient cells
CAMBRIDGE, Mass. – September 23, 2021 – Garuda Therapeutics, a company creating off-the-shelf, durable blood stem cell therapies, launched today with an oversubscribed $72 million Series A financing … read more →
September
23
2021
One platform, 70 diseases and $72 million — these underpin the launch of Garuda Therapeutics, a new stem cell startup founded by Harvard professor Dhvanit Shah… read more →
September
23
2021
We know blood stem cell transplants are potential cures for serious diseases. The problem is, patients need cells from immune-compatible donors, creating a supply bottleneck that constrains use in some areas and blocks expansion into new diseases. Garuda Therapeutics thinks it may have… read more →
September
23
2021
A stem cell researcher who spent time at the Harvard Stem Cell Institute, the Broad Institute and Brigham and Women’s Hospital launched a new biotech Thursday, and he’s attracted significant blue-chip investment to get things up and running…. read more →
Join Us
We are seeking team members who share our passion for science, work ethic, and sense of urgency to improve patients’ lives.